Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Niyati Sheth

Infectious Disease Lorain, OH Doctor of Osteopathy

NPI 1508063090 CMS profile 1032600

3600 Kolbe Rd Ste 206, Lorain, OH 44053

Open in the dashboard

General payments

$975

41 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Niyati Sheth of Lorain, OH is reported in the CMS Open Payments database as having received $975 across 41 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $21 1
2023 General $72 3
2022 General $31 2
2021 General $139 3
2020 General $276 14
2019 General $436 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Niyati Sheth
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to Niyati Sheth were reported at $21. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year Niyati Sheth Infectious Disease median Middle half National median
2019 $436 $190 $60–$862 $163
2020 $276 $124 $32–$606 $114
2021 $139 $148 $38–$905 $132
2022 $31 $166 $50–$834 $149
2023 $72 $171 $57–$787 $160
2024 $0 $176 $52–$752 $164
2025 $21 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $229 13 payments
  2. Janssen Biotech, Inc. $170 6 payments
  3. Gilead Sciences, Inc. $155 9 payments
  4. Melinta Therapeutics, Inc. $109 5 payments
  5. ViiV Healthcare Company $102 5 payments
  6. Janssen Products, LP $99 1 payment
  7. Medtronic Vascular, Inc. $87 1 payment
  8. AbbVie, Inc. $23 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $876 40 payments
  2. Education $99 1 payment
Products named General payments · program years 2019–2025
  1. SYMTUZA $241 6 payments
  2. PIFELTRO $112 6 payments
  3. DELSTRIGO $112 6 payments
  4. ISENTRESS $112 6 payments
  5. DIFICID $110 6 payments
  6. ZERBAXA $102 6 payments
  7. DOVATO $67 3 payments
  8. Vabomere $54 1 payment
  9. CABENUVA $35 2 payments
  10. RECARBRIO $35 2 payments
  11. Other $169 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

141

Median for Infectious Disease: 268

Drug cost

$260,870

Median for Infectious Disease: $217,595

Branded share of claims

63.1%

Median for Infectious Disease: 45.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cabenuva Cabotegravir/Rilpivirine Brand 21 $151,067
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 25 $107,987
Vancomycin Hcl Generic 11 $784
Doxycycline Hyclate Generic 20 $461
Cephalexin Generic 21 $343
Sodium Chloride 0.9 % Sodium Chloride Brand 19 $146
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 24 $82

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$33,868

Medicare's payments for the services billed

Medicare patients

160

Average age 75

Services billed

454

91 women, 69 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 68%
Diabetes 58%
Chronic kidney disease 58%
Ischemic heart disease 57%
Depression 52%
COPD 51%
Heart failure 49%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

41 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Infectious Disease in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record